NuPAGE™ 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein Gel, 12-well, 2 gels (1 box) - Citations
NuPAGE™ 4 to 12%, Bis-Tris, 1.0 mm, Mini Protein Gel, 12-well, 2 gels (1 box) - Citations
View additional product information for NuPAGE™ Bis-Tris Mini Protein Gels, 4–12%, 1.0–1.5 mm - Citations (NP0335PK2, NP0322BOX, NP0327BOX, NP0321BOX, NP0326BOX, NP0330BOX, NP0323BOX, NP0324BOX, NP0329PK2, NP0322PK2, NP0321PK2, NP0336BOX, NP0323PK2, NP0335BOX, NP0329BOX, NP0336PK2)
Showing 1 product Citations
Citations & References
Abstract
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.
AuthorsGraff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG,
JournalJ Clin Invest
PubMed ID17786246
Expression of eukaryotic translation initiation factor 4E (eIF4E) is commonly elevated in human and experimental cancers, promoting angiogenesis and tumor growth. Elevated eIF4E levels selectively increase translation of growth factors important in malignancy (e.g., VEGF, cyclin D1) and is thereby an attractive anticancer therapeutic target. Yet to date, no eIF4E-specific ... More